Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine. Thomas has app. 27K+ followers @LinkedIn being a recognized thought leader regarding emerging trends, technologies and the convergence of technologies and business models that drive the disruption of healthcare and related industries. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight. Prior to InnVentis, he was an associate at deep innovation GmbH, a boutique consultancy and spin-off of Vodafone Group R&D Germany serving governments and global player regarding digitization in healthcare and biomedical R&D. In 1998 he founded a drug discovery company in Munich as CEO/CSO with a focus on inflammatory and metabolic diseases after winning a startup competition. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions in the EU and US at leading academic institutions before becoming an entrepreneur. Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.
Other activities and affiliations; Keynote speaker on Precision Medicine and digitization (selected recent invited talks 2018/19):
Chairmen and organizer of an event with the support of the Bavarian Biotech and Medtech clusters Bio-M and Medical Valley: Chairman, 2nd International Congress on Precision Medicine, October 14/15 2019; http://www.pmbc2019.com/ FORUM SCIENCE & HEALTH Munich July 4th organized by the Bavarian Biotech and Medtech Clusters https://www.forum-science-health.org/ Artificial Intelligence and Big Data in Pharma, Impact on drug development on the role of the industry, Munich June 5th https://www.mpg-alumni.de/conferences/aiworkshop/ 9th Gene Quantification Event. Next Generation Biomarkers – Liquid Biopsy, Multi-Omics,
MicroGenomics Technical University of Munich, Germany http://www.qpcr-dpcr-ngs-2019.net/ AI in Pharmaceutical Industry Summit, February 21-22nd 2019 in Munich, Germany https://curtiswyss.com/events/ai-healthcare Panel and Faculty 1st Digital Rheumatology Day, February 1st Lausanne, CH https://www.digitalrheumatology.org/index Keynote and workshop on Precision Medicine @ High-Tech Partnering Conference January 29th 2019 https://htpc19.converve.io/index.html Precision Medicine World conference Silicon Valley January 21-23, Santa Clara US, https://www.pmwcintl.com/thomas-wilckens-2019sv/ Xiong’An International Health, November 13-15 www.wh-forum.org Bioindustry Park Canavese, Memorial Tribute to Silvano Fumero former CSO Serono, CH (now part of Merck); September 23 http://www.bioindustrypark.eu/?s=wilckens Video of the Precision Medicine World Conference Silicon Valley 2018 on stage with Verliy https://verily.com and Calico https://www.calicolabs.com/ , companies with billion US $ funding from Google. Thomas also serves as an advisor in internal workshops or Q&A sessions at board/SVP level; for example at https://www.medtecheurope.org/ and in several workshops of globally leading companies in healthcare and medicine; more references upon request.